Vienna, VA, May 6, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM)announced today that it has commenced an underwritten public offering of $35.0 million of its common stock. CEL-SCI intends to grant the underwriter a 30-day option to purchase up to an additional $5.25 million of its common stock. FBR Capital Markets & Co. is acting as sole book-running manager for the offering.

CEL-SCI intends to use the net proceeds from the offering primarily to complete patient enrollment in its Phase 3 clinical trial of Multikine (Leukocyte Interleukin, Injection) as a neoadjuvant therapy for patients with squamous cell carcinoma of the head and neck, to fund the Phase 1 trial of Multikine in HIV/HPV co-infected patients with anal warts, to repay a $1.1 million note upon maturity in July 2015 and for general corporate purposes.

The offering will be made by CEL-SCI pursuant to a shelf registration statement on Form S-3 declared effective by the Securities and Exchange Commission ("SEC") on July 8, 2014. A preliminary prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC's website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained from FBR Capital Markets & Co., Attention: Syndicate Prospectus Department, 1300 North 17th Street, Arlington, Virginia 22209, Telephone: 703-312-9500, Email: prospectuses@fbr.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or other jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of CEL-SCI's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's SEC filings, including but not limited to its report on Forms 10-K and 10-K/A for the year ended September 30, 2014. CEL-SCI undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.